Eli Lilly has expanded its glucagon-like peptide portfolio in an intriguing direction by licensing a phase 2-stage GLP-2 agonist from Hanmi Pharm.
Morbi et tellus imperdiet, aliquam nulla sed, dapibus erat. Aenean dapibus sem non purus venenatis vulputate. Donec accumsan eleifend blandit. Nullam auctor ligula
Eli Lilly has expanded its glucagon-like peptide portfolio in an intriguing direction by licensing a phase 2-stage GLP-2 agonist from Hanmi Pharm.